144 related articles for article (PubMed ID: 8176862)
1. [Dosimetry and radiation dose distribution in tumors for radioimmunotherapy: the effect of tumor size].
Fujimori K; Furudate M
Kaku Igaku; 1994 Mar; 31(3):241-8. PubMed ID: 8176862
[TBL] [Abstract][Full Text] [Related]
2. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.
Leichner PK; Kwok CS
Med Phys; 1993; 20(2 Pt 2):529-34. PubMed ID: 8492761
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry models for radioimmunotherapy.
Langmuir VK; Sutherland RM
Med Phys; 1988; 15(6):867-73. PubMed ID: 3237144
[TBL] [Abstract][Full Text] [Related]
4. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
5. Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
Bao A; Zhao X; Phillips WT; Woolley FR; Otto RA; Goins B; Hevezi JM
Med Phys; 2005 Jan; 32(1):200-8. PubMed ID: 15719971
[TBL] [Abstract][Full Text] [Related]
6. Experimental radioimmunotherapy.
Buchsbaum DJ; Langmuir VK; Wessels BW
Med Phys; 1993; 20(2 Pt 2):551-67. PubMed ID: 8492764
[TBL] [Abstract][Full Text] [Related]
7. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors.
Howell RW; Rao DV; Sastry KS
Med Phys; 1989; 16(1):66-74. PubMed ID: 2921982
[TBL] [Abstract][Full Text] [Related]
8. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres.
Bardiès M; Chatal JF
Phys Med Biol; 1994 Jun; 39(6):961-81. PubMed ID: 15551573
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
12. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy.
Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
14. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.
O'Donoghue JA; Bardiès M; Wheldon TE
J Nucl Med; 1995 Oct; 36(10):1902-9. PubMed ID: 7562062
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis.
Fujimori K
Hokkaido Igaku Zasshi; 1991 May; 66(3):369-84. PubMed ID: 1885162
[TBL] [Abstract][Full Text] [Related]
16. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration.
Bernhardt P; Ahlman H; Forssell-Aronsson E
Med Phys; 2004 Sep; 31(9):2628-35. PubMed ID: 15487746
[TBL] [Abstract][Full Text] [Related]
17. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
18. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
Flynn AA; Pedley RB; Green AJ; Dearling JL; El-Emir E; Boxer GM; Boden R; Begent RH
Radiat Res; 2003 Feb; 159(2):182-9. PubMed ID: 12537523
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry of solid tumors.
Meredith RF; Johnson TK; Plott G; Macey DJ; Vessella RL; Wilson LA; Breitz HB; Williams LE
Med Phys; 1993; 20(2 Pt 2):583-92. PubMed ID: 8492767
[TBL] [Abstract][Full Text] [Related]
20. Calculation of radiation doses for nonuniformity distributed beta and gamma radionuclides in soft tissue.
Kwok CS; Prestwich WV; Wilson BC
Med Phys; 1985; 12(4):405-12. PubMed ID: 4033585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
